重组人生长激素治疗儿童生长激素缺乏症和特发性矮小症的安全性问题
Safety of Recombinant Human Growth Hormone in Treating Children with Growth Hormone Deficiency and Idiopathic Short Stature
查看参考文献15篇
|
文摘
|
重组人生长激素的安全性总体较好,但也有少量不良反应出现,如水钠潴留、良性颅内高压、胰岛素敏感性下降、继发肿瘤发生的危险性升高、脊柱侧凸、股骨头滑脱等,但总体发生率较低。 |
|
其他语种文摘
|
Recombinant human growth hormone is generally safe in treating children with growth hormone deficiency and idiopathic short stature.However,side effects such as sodium and water retention,benign intracranial hypertension,insulin insensitivity,increasing risk of secondary neoplasm,scoliosis,and slipped capital femoral epiphysis may occur occasionally,although the overall incidence remains low. |
|
来源
|
中国医学科学院学报
,2011,33(2):123-126 【核心库】
|
|
DOI
|
10.3881/j.issn.1000-503x.2011.02.005
|
|
关键词
|
重组人生长激素
;
生长激素缺乏症
;
特发性矮小
;
不良反应
|
|
地址
|
中国医学科学院北京协和医学院北京协和医院内分泌科, 北京, 100730
|
|
语种
|
中文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
1000-503X |
|
学科
|
内科学 |
|
文献收藏号
|
CSCD:4191956
|
参考文献 共
15
共1页
|
|
1.
Clayton PE. Safety issues in children and adolescents during growth hormone therapy-a review.
Growth Horm IGF Res,2000,10(6):306-317
|
被引
3
次
|
|
|
|
|
2.
Burgert TS. Assessing insulin resistance: application of a fasting glucose to insulin ratio in growth hormone-treated children.
Horm Res,2002,57(1/2):37-42
|
被引
2
次
|
|
|
|
|
3.
Quigley CA. Safety of growth hormone treatment in pediatric patients with idiopathic short stature.
J Clin Endocrinol Metab,2005,90(9):5188-5196
|
被引
4
次
|
|
|
|
|
4.
Blethen SL. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the National Cooperative Growth Study experience.
J Clin Endocrinol Metab,1996,81(5):1704-1710
|
被引
6
次
|
|
|
|
|
5.
Cowell CT. Adverse events during growth hormone therapy.
J Pediatr Endocrinol Metab,1995,8(4):243-252
|
被引
4
次
|
|
|
|
|
6.
Cutfield WS. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment.
Lancet,2000,355(9204):610-613
|
被引
6
次
|
|
|
|
|
7.
唐丹. 重组人生长激素治疗生长激素缺乏症20例.
中华医学杂志,1997,35(6):468
|
被引
10
次
|
|
|
|
|
8.
Ranke MB. Adverse events during GH treatment: 10 years' experience in KIGS, a pharmacoepidemiological survey.
Progress in growth hormone therapy-10 years of KIGS,1999:349-364
|
被引
1
次
|
|
|
|
|
9.
Shalet SM. Growth hormone therapy and malignancy.
Horm Res,1997,48(Suppl 4):29-32
|
被引
1
次
|
|
|
|
|
10.
Allen DB. Risk of leukemia in children treated with human growth hormone: review and reanalysis.
J Pediatr,1997,131(1 Pt 2):S32-S36
|
被引
1
次
|
|
|
|
|
11.
Swerdlow AJ. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study.
Lancet,2002,360(9329):273-277
|
被引
4
次
|
|
|
|
|
12.
Tuffli GA. Lack of increased risk for extracranial, nonleukemic neoplasms in recipients of recombinant deoxyribonucleic acid growth hormone.
J Clin Endocrinol Metab,1995,80(4):1416-1422
|
被引
1
次
|
|
|
|
|
13.
Darendeliler F. Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database).
Acta Paediatr,2006,95(10):1284-1290
|
被引
3
次
|
|
|
|
|
14.
Bell J. Long-term safety of recombinant human growth hormone in children.
J Clin Endocrinol Metab,2010,95(1):167-177
|
被引
14
次
|
|
|
|
|
15.
Sklar CA. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study.
J Clin Endocrinol Metab,2002,87(7):3136-3141
|
被引
7
次
|
|
|
|
|
了解气象卫星更多信息，请访问